Assessment of CMV-specific ELISPOT Assay for Predicting CMV Co-infection in Patients With Pneumocystitis Pneumonia (ACE-PCP)
Assessment of CMV-specific ELISPOT Assay for Predicting CMV Co-infection in Patients With Pneumocystitis Pneumonia (ACE-PCP)
PCP (Pneumocystis jiroveci pneumonia) is one of the important opportunistic infections in
 immunocompromised patients including HIV-infected patients, transplant recipients, and
 immunosuppressant users. About one third of non-HIV patients with PCP have the evidence of
 co-infection with CMV. In this difficult clinical situation, physicians have difficulty to
 decide on whether anti-CMV treament will help patients with any evidence of CMV co-infection.
 However, there is no objective test to differentiate true co-infection of CMV from innocent
 bystander of CMV in those with PCP. The investigators thus evaluate the usefulness of
 CMV-specific ELISPOT assay in patients with PCP to differentiate true co-infection of CMV
 from inocent bystander of CMV. This findings may guide physicians to decide anti-CMV
 treatment in patients with PCP and CMV co-infection.
PCP (Pneumocystis jiroveci pneumonia) is one of the important opportunistic infections in
 immunocompromised patients including HIV-infected patients, transplant recipients, and
 immunosuppressant users. About one third of non-HIV patients with PCP have the evidence of
 co-infection with CMV. In this difficult clinical situation, physicians have difficulty to
 decide on whether anti-CMV treament will help patients with any evidence of CMV co-infection.
 However, there is no objective test to differentiate true co-infection of CMV from innocent
 bystander of CMV in those with PCP. The investigators thus evaluate the usefulness of
 CMV-specific ELISPOT assay in patients with PCP to differentiate true co-infection of CMV
 from inocent bystander of CMV. This findings may guide physicians to decide anti-CMV
 treatment in patients with PCP and CMV co-infection.
Inclusion Criteria:

 -  diagnosis of PCP based on PCP immunohistochemistry or PCP PCR

 -  age 16 or more

 -  agree with written informed consent

 -  WBC count 2000/uL or more

 Exclusion Criteria:

 -  HIV infection